MPP aims to improve access to affordable #EssentialMedicines – including for treating #HIV #ViralHepatitis #TB #COVID-19 and #NCDs – in low- and middle-income countries through voluntary licensing and technology transfer.
medicinespatentpool.org
Medicines Patent Pool
Loading...
⏳ Only 2 days left!
📅 Friday, 12 June 2026
🕐 13:00–14:30 CET / 16:30–18:00 IST
💻 Virtual meeting
👉 Register: events.teams.microsoft.com/event/01ad7c...
#baloxavirmarboxil #GenericManufacturing #VoluntaryLicensing
📢 Join MPP’s webinar on the Baloxavir Marboxil Licence Expression of Interest (EOI) process.
👉 Register here: events.teams.microsoft.com/event/01ad7c...
We encourage interested companies to attend and participate in the discussion.
#BaloxavirMarboxil #Roche #Genericmanufacture #voluntarylicensing
🌍 We're hiring a Health Technologies Manager
Join the @medicinespatentpool.org and help advance access to life-saving health technologies through technology transfer, local manufacturing, and global partnerships.
👉 lnkd.in/eMykRWU7
📅 Apply by 18 June 2026.
#TechnologyTransfer #PublicHealth
Demonstrating continued and sustained impact for people in low- and middle-income countries (LMICs), MPP today publishes its 2025 annual report, From Innovation to Access.
👉 Download MPP's 2025 Annual Report: medicinespatentpool.org/news-publica...
📢 The June 2026 MPP Newsletter is out!
👉 Read the newsletter: mailchi.mp/medicinespat...
📩 To subscribe: medicinespatentpool.org/news-publica...
Happy reading!
💡 Did you know?
#MedsPaL is a free resource providing crucial information on the intellectual property status of patented essential medicines in LMICs, patent information on COVID-19 and Mpox vaccines, and long-acting platform technologies worldwide.
👉 www.medspal.org
At #WHA79, MPP welcomed the renewed commitment to accelerate progress towards malaria elimination.
Public health-oriented #voluntarylicensing helps expand access to innovative medicines by reducing delays, lowering costs, and strengthening supply security.
👉 medicinespatentpool.org/news-publica...
At #ASCO26, the conversation is rightly focused on #innovation.
@medicinespatentpool.org is a partner of choice to explore how innovation can reach patients in LMICs in a sustainable way while generating #value for patent holders.
Today at #WHA79, MPP and Roche celebrated the signing of a public health-oriented voluntary licence agreement for baloxavir marboxil, an #influenza antiviral treatment recommended by @who.int.
Read the announcement: bit.ly/4wwZsW1
@unitaid.bsky.social @drduneton.bsky.social
Medicines Patent Pool
At #WHA79, MPP highlighted the role of non-exclusive licensing and technology transfer in advancing the equity objectives of the @who.int Pandemic Agreement.
medicinespatentpool.org/news-publica...
#GlobalHealth #PandemicPreparedness #HealthEquity
Medicines Patent Pool
Medicines Patent Pool
The Medicines Patent Pool (MPP) and Roche have signed a voluntary licence agreement to expand access to baloxavir marboxil (Xofluza®), an innovative antiviral treatment for influenza recommended by th...
Monday 18 May Item 13.3 – Open-ended Intergovernmental Working Group on the WHO Pandemic Agreement STATEMENT Delivered by Hillary Mutungi We commend negotiators for their continued efforts to build co...
Monday, 18 May 2026 – Committee A Agenda item 13.3 – Open-ended Intergovernmental Working Group on the WHO Pandemic Agreement STATEMENT Delivered by Hillary Mutungi We commend negotiators for their co...
Demonstrating its continued and sustained impact on the lives of people in low- and middle-income countries (LMICs) across the world, the Medicines Patent Pool (MPP) today publishes its 2025 annual re...
